Bilezikian JP, Bandeira L, Khan A, Cusano NE. Hyperparathyroidism. Lancet. 2018;391:168–78. https://doi.org/10.1016/S0140-6736(17)31430-7.

Article  CAS  PubMed  Google Scholar 

Al-Salameh A, Cadiot G, Calender A, Goudet P, Chanson P. Clinical aspects of multiple endocrine neoplasia type 1. Nat Rev Endocrinol. 2021;17:207–24. https://doi.org/10.1038/s41574-021-00468-3.

Article  PubMed  Google Scholar 

Vinault S, Mariet AS, Le Bras M, Mirallie E, Cardot-Bauters C, Pattou F, et al. Metastatic potential and survival of duodenal and pancreatic tumors in multiple endocrine neoplasia type 1: a GTE and AFCE cohort study (Groupe d’etude des Tumeurs Endocrines and Association Francophone de Chirurgie Endocrinienne). Ann Surg. 2020;272:1094–101. https://doi.org/10.1097/SLA.0000000000003162.

Article  PubMed  Google Scholar 

Ito T, Igarashi H, Uehara H, Berna MJ, Jensen RT. Causes of death and prognostic factors in multiple endocrine neoplasia type 1: a prospective study: comparison of 106 MEN1/Zollinger-Ellison syndrome patients with 1613 literature MEN1 patients with or without pancreatic endocrine tumors. Medicine (Baltimore). 2013;92:135–81. https://doi.org/10.1097/MD.0b013e3182954af1.

Article  CAS  PubMed  Google Scholar 

Norton JA, Krampitz G, Zemek A, Longacre T, Jensen RT. Better survival but changing causes of death in patients with multiple endocrine neoplasia type 1. Ann Surg. 2015;261:e147–8. https://doi.org/10.1097/SLA.0000000000001211.

Article  PubMed  Google Scholar 

Goudet P, Murat A, Binquet C, Cardot-Bauters C, Costa A, Ruszniewski P, et al. Risk factors and causes of death in MEN1 disease. A GTE (Groupe d’Etude des Tumeurs Endocrines) cohort study among 758 patients. World J Surg. 2010;34:249–55. https://doi.org/10.1007/s00268-009-0290-1.

Article  PubMed  Google Scholar 

Gibril F, Chen YJ, Schrump DS, Vortmeyer A, Zhuang Z, Lubensky IA, et al. Prospective study of thymic carcinoids in patients with multiple endocrine neoplasia type 1. J Clin Endocrinol Metab. 2003;88:1066–81. https://doi.org/10.1210/jc.2002-021314.

Article  CAS  PubMed  Google Scholar 

Gaujoux S, Martin GL, Mirallie E, Regenet N, Le Bras M, Pattou F, et al. Life expectancy and likelihood of surgery in multiple endocrine neoplasia type 1: AFCE and GTE cohort study. Br J Surg. 2022;109:872–9. https://doi.org/10.1093/bjs/znac006.

Article  PubMed  Google Scholar 

Thakker RV, Newey PJ, Walls GV, Bilezikian J, Dralle H, Ebeling PR, et al. Clinical practice guidelines for multiple endocrine neoplasia type 1 (MEN1). J Clin Endocrinol Metab. 2012;97:2990–3011. https://doi.org/10.1210/jc.2012-1230.

Article  CAS  PubMed  Google Scholar 

Santucci N, Ksiazek E, Pattou F, Baud G, Mirallie E, Frey S, et al. Recurrence after surgery for primary hyperparathyroidism in 517 patients with multiple endocrine neoplasia type 1. An AFCE and GTE study (Association Francophone de Chirurgie Endocrinienne and Groupe d'etude des Tumeurs Endocrines). Ann Surg. 2023. https://doi.org/10.1097/SLA.0000000000005980.

Nilubol N, Weinstein LS, Simonds WF, Jensen RT, Marx SJ, Kebebew E. Limited parathyroidectomy in multiple endocrine neoplasia type 1-associated primary hyperparathyroidism: a setup for failure. Ann Surg Oncol. 2016;23:416–23. https://doi.org/10.1245/s10434-015-4865-9.

Article  PubMed  Google Scholar 

Versnick M, Popadich A, Sidhu S, Sywak M, Robinson B, Delbridge L. Minimally invasive parathyroidectomy provides a conservative surgical option for multiple endocrine neoplasia type 1-primary hyperparathyroidism. Surgery. 2013;154:101–5. https://doi.org/10.1016/j.surg.2013.03.004.

Article  PubMed  Google Scholar 

Choi HR, Choi SH, Choi SM, Kim JK, Lee CR, Kang SW, et al. Benefit of diverse surgical approach on short-term outcomes of MEN1-related hyperparathyroidism. Sci Rep. 2020;10:10634. https://doi.org/10.1038/s41598-020-67424-5.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Treglia G, Piccardo A, Imperiale A, Strobel K, Kaufmann PA, Prior JO, et al. Diagnostic performance of choline PET for detection of hyperfunctioning parathyroid glands in hyperparathyroidism: a systematic review and meta-analysis. Eur J Nucl Med Mol Imaging. 2019;46:751–65. https://doi.org/10.1007/s00259-018-4123-z.

Article  CAS  PubMed  Google Scholar 

Cuderman A, Senica K, Rep S, Hocevar M, Kocjan T, Sever MJ, et al. (18)F-Fluorocholine PET/CT in primary hyperparathyroidism: superior diagnostic performance to conventional scintigraphic imaging for localization of hyperfunctioning parathyroid glands. J Nucl Med. 2020;61:577–83. https://doi.org/10.2967/jnumed.119.229914.

Article  CAS  PubMed  Google Scholar 

Petranovic Ovcaricek P, Giovanella L, Carrio Gasset I, Hindie E, Huellner MW, Luster M, et al. The EANM practice guidelines for parathyroid imaging. Eur J Nucl Med Mol Imaging. 2021;48:2801–22. https://doi.org/10.1007/s00259-021-05334-y.

Article  PubMed  PubMed Central  Google Scholar 

Gauthe M, Dierick-Gallet A, Delbot T, Bricaire L, Bertherat J, North MO, et al. (18)F-fluorocholine PET/CT in MEN1 patients with primary hyperparathyroidism. World J Surg. 2020;44:3761–9. https://doi.org/10.1007/s00268-020-05695-9.

Article  PubMed  Google Scholar 

Talbot JN, Zhang-Yin J, Kerrou K, Aveline C, Vagne B, Belissant O, et al. Multiple endocrine neoplasia type 1 or 4: detection of hyperfunctioning parathyroid glands with 18F-fluorocholine PET/CT. Illustrative cases and pitfalls. Q J Nucl Med Mol Imaging. 2022;66:130–40. https://doi.org/10.23736/S1824-4785.22.03440-9.

Article  PubMed  Google Scholar 

Kluijfhout WP, Vorselaars WM, van den Berk SA, Vriens MR, Borel Rinkes IH, Valk GD, et al. Fluorine-18 fluorocholine PET-CT localizes hyperparathyroidism in patients with inconclusive conventional imaging: a multicenter study from the Netherlands. Nucl Med Commun. 2016;37:1246–52. https://doi.org/10.1097/MNM.0000000000000595.

Article  CAS  PubMed  Google Scholar 

Huber GF, Hullner M, Schmid C, Brunner A, Sah B, Vetter D, et al. Benefit of (18)F-fluorocholine PET imaging in parathyroid surgery. Eur Radiol. 2018;28:2700–7. https://doi.org/10.1007/s00330-017-5190-4.

Article  CAS  PubMed  Google Scholar 

Grimaldi S, Young J, Kamenicky P, Hartl D, Terroir M, Leboulleux S, et al. Challenging pre-surgical localization of hyperfunctioning parathyroid glands in primary hyperparathyroidism: the added value of (18)F-fluorocholine PET/CT. Eur J Nucl Med Mol Imaging. 2018;45:1772–80. https://doi.org/10.1007/s00259-018-4018-z.

Article  CAS  PubMed  Google Scholar 

Fischli S, Suter-Widmer I, Nguyen BT, Muller W, Metzger J, Strobel K, et al. The significance of 18F-fluorocholine-PET/CT as localizing imaging technique in patients with primary hyperparathyroidism and negative conventional imaging. Front Endocrinol (Lausanne). 2017;8:380. https://doi.org/10.3389/fendo.2017.00380.

Article  PubMed  Google Scholar 

Broos WAM, Wondergem M, Knol RJJ, van der Zant FM. Parathyroid imaging with (18)F-fluorocholine PET/CT as a first-line imaging modality in primary hyperparathyroidism: a retrospective cohort study. EJNMMI Res. 2019;9:72. https://doi.org/10.1186/s13550-019-0544-3.

Article  PubMed  PubMed Central  Google Scholar 

Hindie E, Schwartz P, Avram AM, Imperiale A, Sebag F, Taieb D. Primary hyperparathyroidism: defining the appropriate preoperative imaging algorithm. J Nucl Med. 2021;62:3S-12S. https://doi.org/10.2967/jnumed.120.245993.

Article  CAS  PubMed  Google Scholar